Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. LGND has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
LGND stock price ended at $108.07 on , after losing-0.44%
The Ligand Pharmaceuticals Inc stock price decreased by -0.44% on the last trading day (), dropping from 106.95 to 108.07. Throughout the last trading session, the stock experienced a fluctuation of 3.53% , ranging from a day low of $104.65 to a day high of 108.34. The price has declined in 4 of the last 10 days, resulting in a total change of 6.69% during this period. On the last day, trading volume decrease by 22.42K shares, with the falling prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 102.96K shares were traded, amounting to approximately 10.96M.
LGND Technical Signals
LGND(Ligand Pharmaceuticals Inc Corp) has buy signals and sell signals now. The average turnover of LGND over the last 5 trading days is NaN. Overall, the technical indicator signals lean more toward a outlook in the mid-term.
LGND Moving Average Analysis
Ligand Pharmaceuticals Inc's overall moving average trend leans more bullish as of Monday, April 28, 2025, with 1 negative signals and 3 positive signal. In the mid-term, the SMA_20 being below the SMA_60 signals a strong bearish trend. There will be some resistance from the lines at $, and $. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $, and $. A break-down below any of these levels will issue sell signals.
LGND Short Selling Analysis
The short sale ratio of Ligand Pharmaceuticals Inc(LGND) as of is %, dropping from last trading day. With decreasing price from to .
Technical Signal
Technical Signals Summary
Sell
Buy
Moving Average
Swing
Negative
Stock Price Below SMA_5
Short Term
Negative
SMA_5 Below SMA_20
Mid Term
Negative
SMA_20 Below SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
Bullish Signals
0 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
No Data
Bearish Signals
0 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
No Data
LGND
Name
Similarity
Up/Down
No Data
LGND Seasonality Analysis
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying Ligand Pharmaceuticals Inc (LGND.O) stock in has the highest probability of a positive return (%), while has the lowest probability (%).
Performance Seasonality
The chart shows Ligand Pharmaceuticals Inc. (LGND)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
People Also Watch
FAQ
Should I buy Ligand Pharmaceuticals Inc (LGND.O) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. LGND has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
Which months have the highest win rate for buying Ligand Pharmaceuticals Inc (LGND.O) stock in a year?
The radar chart shows that buying Ligand Pharmaceuticals Inc (LGND.O) stock in has the highest probability of a positive return (63.64%), while has the lowest probability (63.64%).
How has Ligand Pharmaceuticals Inc. (LGND)'s stock price performed over the past three years?
LGND's stock price fell by in Invalid Date,in by
Which bull technical signals does LGND have?
Bullish technical signals of LGND include:
Which bearish technical signals does LGND have?
Bearish technical signals of LGND include:
Is LGND a buy based on overall technical signals summary?
LGND has 2 buy signals and 3 sell signals now. Overall the technical rating for LGND is . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of LGND.
What is the trend of Ligand Pharmaceuticals Inc (LGND)'s moving average?
Ligand Pharmaceuticals Inc's overall moving average trend leans more bullish as of April 28 2025, with 3 negative signals and 1 positive signal.
What is price prediction for LGND stock next month?
The price prediction chart for Ligand Pharmaceuticals Inc (LGND.O) stock, as of Invalid Date, forecasts a % change over the next month, based on its high correlation with stock patterns. The similarity between their price movements over the analyzed periods is %. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for LGND Stock?
Ligand Pharmaceuticals (LGND) is expected to reach a price target of **$143** by 2025, driven by its diversified royalty portfolio and strong growth prospects in the biopharma sector. The stock is currently trading at **$102.5**, with technical indicators suggesting potential upside. Analysts have initiated coverage with a **Strong Buy** rating, highlighting Ligand's capital-efficient business model and over 20% growth potential through 2029.
What is price prediction 2030 for LGND Stock?
### **Price Prediction for LGND Stock by 2030**
Based on current trends and recent developments, LGND stock is predicted to reach **$150 by 2030**. This forecast is supported by the company's strong financial guidance, including a 2025 revenue target of $180-200 million and a long-term royalty CAGR of 22%. The merger with Channel Therapeutics and the launch of Zelsuvmi are expected to drive growth and diversify revenue streams, positioning LGND for sustained appreciation.